A major event for new tuberculosis vaccines.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.BMC infectious diseases · 2014
   Trial
2. Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.European journal of immunology · 2013
   Trial
3. Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development.NPJ vaccines · 2024
   Review
4. Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens.Journal of clinical microbiology · 2016
   Article
5. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
   Article
6. Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF.Infection and immunity · 2015
   Article
7. Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.Expert review of vaccines · 2015
   Review
8. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.Proceedings of the National Academy of Sciences of the United States of America · 2014
   Article
9. Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations.Vaccines · 2014
   Review
10. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.PloS one · 2014
    Article
11. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.Journal of the Royal Society, Interface · 2013
    Article
12. Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.PloS one · 2013
    Article
13. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.PloS one · 2013
    Article

Corrections and comments

• Comment on
  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as